Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000902664-25-002963·Celldex Therapeutics, Inc.
Schedule 13G ownership disclosure
Celldex Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 15117B202
Event date: 2025-07-02
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 4,464,400.00 · Class: 6.7%
- Point72 Capital Advisors, Inc.
Shares: 4,464,400.00 · Class: 6.7%
- Steven A. Cohen
Shares: 4,464,400.00 · Class: 6.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002963
- Form type
- SCHEDULE 13G
- Filer
- Celldex Therapeutics, Inc.
- CIK
- CIK 744218
- Filed
- Jul 10, 2025
- Reporting period
- Jul 02, 2025
- Description
- Schedule 13G beneficial ownership